当前位置:首页 - 行情中心 - 药易购(300937) - 财务分析 - 利润表

药易购

(300937)

  

流通市值:16.74亿  总市值:25.45亿
流通股本:6291.82万   总股本:9566.67万

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入2,157,138,212.151,137,614,693.124,380,809,520.013,235,469,610.27
  营业收入2,157,138,212.151,137,614,693.124,380,809,520.013,235,469,610.27
二、营业总成本2,136,963,938.031,120,320,821.964,346,174,702.443,211,095,776.4
  营业成本1,923,742,125.351,011,930,212.473,990,533,313.192,956,968,916.08
  税金及附加4,399,057.782,245,916.748,866,486.165,808,090.97
  销售费用164,102,280.1384,234,538.85251,435,378.16180,912,080.87
  管理费用34,477,443.1116,560,922.6170,980,183.2348,263,363.14
  研发费用5,619,039.062,770,134.2215,467,329.8712,565,314.67
  财务费用4,623,992.62,579,097.078,892,011.836,578,010.67
  其中:利息费用4,519,758.882,470,053.979,710,490.087,392,613.53
  其中:利息收入1,435,151.29653,293.933,872,883.433,182,109.29
三、其他经营收益
  加:投资收益622,828.29441,202.7-1,835,026.32-468,072.44
  资产处置收益121,117.81-1,927.82-606,269.06-496,970.1
  资产减值损失(新)-6,409,931.62-1,764,225.83-9,929,815.75816,311.42
  信用减值损失(新)-12,660,591.75-10,352,278.65-7,896,914.22-15,381,890.49
  其他收益591,811.03335,999.592,012,202.991,391,409.14
四、营业利润2,439,507.885,952,641.1516,378,995.2110,234,621.4
  加:营业外收入237,746.31109,027.772,103,695.06917,395.36
  减:营业外支出268,919.29176,314.791,305,960.79770,923.93
五、利润总额2,408,334.95,885,354.1317,176,729.4810,381,092.83
  减:所得税费用11,473,266.971,641,829.31,776,820.86-92,078.43
六、净利润-9,064,932.074,243,524.8315,399,908.6210,473,171.26
(一)按经营持续性分类
  持续经营净利润-9,064,932.074,243,524.8315,399,908.6210,473,171.26
(二)按所有权归属分类
  归属于母公司股东的净利润-7,614,393.654,183,729.4216,358,248.0113,931,460.39
  少数股东损益-1,450,538.4259,795.41-958,339.39-3,458,289.13
  扣除非经常损益后的净利润-8,323,130.543,564,041.2212,369,745.769,365,305.81
七、每股收益
  (一)基本每股收益-0.080.040.170.15
  (二)稀释每股收益-0.080.040.170.15
九、综合收益总额-9,064,932.074,243,524.8315,399,908.6210,473,171.26
  归属于母公司股东的综合收益总额-7,614,393.654,183,729.4216,358,248.0113,931,460.39
  归属于少数股东的综合收益总额-1,450,538.4259,795.41-958,339.39-3,458,289.13
公告日期2025-08-122025-04-252025-04-112024-10-25
审计意见(境内)标准无保留意见
TOP↑